James P. Brady
Personalreferent bei SPERO THERAPEUTICS, INC.
Aktive Positionen von James P. Brady
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SPERO THERAPEUTICS, INC. | Personalreferent | - | - |
Karriereverlauf von James P. Brady
Ehemalige bekannte Positionen von James P. Brady
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
UNIQURE N.V. | Personalreferent | 01.08.2020 | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Personalreferent | 01.04.2015 | - |
Ausbildung von James P. Brady
Marietta College | Undergraduate Degree |
Harvard University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Niederlande | 2 |
Operativ
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
UNIQURE N.V. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- James P. Brady
- Erfahrung